13F-HR filed by Saturn V Capital Management LP
Saturn V Capital Management LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 23 holding rows worth $261,248,668.
- Accession
- 0001964437-24-000002
- Filer
- CIK 1964437
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 23 entries on the cover page, a total value of $261,248,668 stated on the cover page (in dollars after the unit check, H1), rows summing to $261,248,668 with VALUE read as dollars as filed, 13F file number 028-22863. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CYTOKINETICS INC | 23282W605 | COM NEW | 448,144 | $37,415,543 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 787,132 | $28,006,157 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 1,807,563 | $22,142,647 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 51,175 | $19,468,505 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 750,250 | $17,720,905 | dollars as filed | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 131,759 | $16,595,046 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 1,099,268 | $16,181,225 | dollars as filed | |
| ANAPTYSBIO INC | 032724106 | COM | 664,276 | $14,228,792 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 119,188 | $11,492,107 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 518,799 | $11,211,246 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 389,333 | $10,706,658 | dollars as filed | |
| ITEOS THERAPEUTICS INC | 46565G104 | COM | 828,232 | $9,069,140 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 142,927 | $8,555,610 | dollars as filed | |
| BIOGEN INC COM | 09062X103 | Stock | 32,469 | $8,402,003 | dollars as filed | |
| ASTRIA THERAPEUTICS INC COM | 04635X102 | Stock | 990,663 | $7,608,292 | dollars as filed | |
| MORPHIC HLDG INC | 61775R105 | COM | 212,343 | $6,132,466 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 756,681 | $4,449,284 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 64,784 | $3,741,924 | dollars as filed | |
| AMICUS THERAPEUTICS INC | 03152W109 | COM | 199,973 | $2,837,617 | dollars as filed | |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 10,327 | $1,976,691 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 160,075 | $1,461,485 | dollars as filed | |
| JASPER THERAPEUTICS INC | 471871103 | COM | 1,386,215 | $1,093,724 | dollars as filed | |
| AMBRX BIOPHARMA INC | 641871108 | COM | 52,781 | $751,601 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001964437-24-000002 | this filing | 2024-02-14 | acceptance time not in the bulk data set |